MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
147.68
-1.72
-1.15%
Opening 11:13 11/19 EST
OPEN
149.59
PREV CLOSE
149.40
HIGH
152.70
LOW
146.51
VOLUME
580.84K
TURNOVER
--
52 WEEK HIGH
479.79
52 WEEK LOW
146.51
MARKET CAP
19.78B
P/E (TTM)
7.48
1D
5D
1M
3M
1Y
5Y
1D
Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
Benzinga · 3h ago
Alnylam Pharma To Receive $25 Mln Payment From Regeneron On FDA Approval Of Livsayis
NASDAQ · 3h ago
Alnylam announces FDA approved Livsayis for treatment of gMG
TipRanks · 3h ago
Regeneron, Alnylam win FDA nod for myasthenia gravis therapy
Seeking Alpha · 3h ago
Pfizer: The Patent Cliff Fears Are Overblown
Seeking Alpha · 1d ago
Alnylam price target lowered to $254 from $369 at JPMorgan
TipRanks · 1d ago
Alnylam price target lowered to $205 from $290 at Cantor Fitzgerald
TipRanks · 2d ago
Alnylam Pharmaceuticals Price Target Cut to $250.00/Share From $455.00 by HC Wainwright & Co.
Dow Jones · 2d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.